Research Article

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF-κB Pathway

Yu Long,¹ Yan Xiang,¹ Songyu Liu,¹ Yulu Zhang,¹ Jinyan Wan,¹ Qiyue Yang,² Mingquan Cui,¹ Zhimin Ci,¹ Nan Li,¹ and Wei Peng¹

¹School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
²Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

Correspondence should be addressed to Nan Li; 55743198@qq.com and Wei Peng; pengwei@cdutcm.edu.cn

Yu Long and Yan Xiang contributed equally to this work.

Received 3 June 2020; Revised 22 September 2020; Accepted 12 October 2020; Published 11 November 2020

Academic Editor: Carla Pagliari

Copyright © 2020 Yu Long et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are challenging diseases with the high mortality in a clinical setting. Baicalin (BA) is the main effective constituent isolated from the Chinese medical herb Scutellaria baicalensis Georgi, and studies have proved that it has a protective effect on ALI induced by lipopolysaccharide (LPS) due to the anti-inflammatory efficacy. However, BA has low solubility which may limit its clinical application. Hence, we prepared a novel drug delivery system—Baicalin liposome (BA-LP) in previous research—which can improve some physical properties of BA. Therefore, we aimed to explore the effect of BA-LP on ALI mice induced by LPS. In pharmacokinetics study, the values of $t_{1/2}$ and $AUC_{0-t}$ in the BA-LP group were significantly higher than that of the BA group in normal mice, indicating that BA-LP could prolong the duration time in vivo of BA. The BA-LP group also showed a higher concentration in lung tissues than the BA group. Pharmacodynamics studies showed that BA-LP had a better effect than the BA group at the same dosage on reducing the W/D ratio, alleviating the lung injury score, and decreasing the proinflammatory factors (TNF-α, IL-1β) and total proteins in bronchoalveolar lavage fluids (BALF). In addition, the therapeutic effects of BA-LP showed a dose-dependent manner. Western blot analysis indicated that the anti-inflammatory action of BA could be attributed to the inhibition of the TLR4-NFκBp65 and JNK-ERK signaling pathways. These results suggest that BA-LP could be a valuable therapeutic candidate in the treatment of ALI.

1. Introduction

Acute lung injury (ALI) is one of the clinically common severe respiratory infection diseases caused by various intrapulmonary and extrapulmonary pathogenic factors [1]. The more severe diffuse lung injury is called acute respiratory distress syndrome (ARDS). ARDS can cause multiple organ dysfunction syndromes in the later stage, which has an extremely serious damage to the human body. ALI, as a basic pathophysiological change of ARDS, is a challenging disease in the clinical setting [2]. It is characterized by the damage of the alveolar capillary system, increased pulmonary vascular permeability, diffuse alveolar injury, intra-alveolar fibrin, interstitial edema, and inflammatory cell infiltration [3]. Although ALI/ARDS has been studied in recent years, there is still a lack of effective ways to reduce its high mortality. Hence, it is urgent to develop a novel effective therapy to intervene in the diseases.

Lipopolysaccharide (LPS) is a pathogenic endotoxin of the outer membranes of Gram-negative bacteria, which is widely used in preparing animal models of ALI [4]. LPS can induce a series of inflammatory responses by the release of some inflammatory cytokines and factors [5]. The emergence and disappearance of inflammation are unique functions of the
immune system, which represents the natural process of the body to repair the injury and remove pathogenic substances. Some inflammatory responses controlled are conducive for the clearing of harmful substances, while some without control may cause fatal injury to the body, such as the inflammation during ALI, which plays an extraordinary role in the course of disease [6, 7]. Hence, it is very important to take measures to eliminate inflammation for the treatment of ALI.

Baicalin (5,6-dihydroxy-7-O-glucuronide flavone, BA) is the main effective constituent isolated from the roots of the Chinese medical herb Scutellaria baicalensis Georgi, which is widely used in pneumonia, hepatitis, atherosclerosis [8], and other conditions. Recent studies have indicated that BA has many pharmacological activities, like anti-inflammation [9], antioxidative stress [10], neuroprotective [11], and antibacterial [12]. Increasing researches have showed that BA has a protective effect on ALI induced by LPS [13]. However, BA has a low solubility due to the existence of glycosyl groups in the molecular structure. And its bioavailability is only 2.2% after oral administration [14], which limits the development and the clinical use of it. Therefore, it is important for us to find a new way to improve some properties of BA.

In the previous study, we prepared a novel drug delivery system, Baicalin liposome (BA-LP) [15], to improve some properties of BA. The data showed that the cumulative release rate of BA-LP in vitro was about 57.43%, while the BA was 95.4%. Therefore, we aimed to explore the effect of BA-LP against the LPS-induced ALI. So, in this research, we researched the pharmacokinetics of BA-LP in normal mice. Then, we compared the therapeutic effects of BA and BA-LP on LPS-induced ALI and explored the underlying molecular mechanisms associated with inflammation by the regulation of the TLR4/MARKs/NF-κB signaling pathways. In this study, we hope to offer some references for the treatment of ALI in the future.

2. Materials and Methods

2.1. Reagents. BA (purity over 90%) was purchased from Nanjing Zelang Biotechnology Co., Ltd. (Nanjing, China). The BA standard agent (No. MUST-19010408, purity over 98%) was obtained from Chengdu Man Site Biotechnology Co., Ltd. (Chengdu, China). The Rutin (RU) standard agent (No. L-001-181216) was purchased from Chengdu Herbpurify Co., Ltd. (Chengdu, China). Cholesterol (No. B80859) and soybean lecithin (200 mg) were fully dissolved in a mixture of chloroform and diethyl ether (1 : 2) to form an organic phase. Then, BA phosphate buffer solution (PBS) (5.2 mg/mL) was injected into the organic at a uniform speed. Put the mixture into the ultrasonic homogenizer for 10 min, 20°C to form an emulsion liquid. After the organic solvent was removed by rotating evaporation, 1 mL PBS was added to hydrate until a yellow and clear solution was formed; then, the BA-LP was obtained.

2.2. Animals. Male KM mice, weighing between 20 and 25 g, were provided by Chengdu Dashuo Laboratory Animal Co., Ltd. (Chengdu, China). The mice were housed in a stabilized laboratory condition with free food and water, the temperature at approximately 24 ± 1°C, and 40% to 80% relative humidity. All procedures in this experiment were performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). And this study protocol was approved by the Chengdu University of Traditional Chinese Medicine Animal Ethical Experimentation Committee with the approval no. 2016KL-027.

2.3. Preparation of BA-LP. BA-LP was prepared by reverse evaporation as our previous research [15]. In short, cholesterol (35 mg) and soybean lecithin (200 mg) were fully dissolved in a mixture of chloroform and diethyl ether (1 : 2) to form an organic phase. Then, BA phosphate buffer solution (PBS) (5.2 mg/mL) was injected into the organic at a uniform speed. Put the mixture into the ultrasonic homogenizer (10 min, 20°C) to form an emulsion liquid. After the organic solvent was removed by rotating evaporation, 1 mL PBS was added to hydrate until a yellow and clear solution was formed; then, the BA-LP was obtained.

2.4. Pharmacokinetics and Tissue Distributions of BA-LP and BA in Normal Mice

2.4.1. Preparation of Plasma and Tissue Samples. Mice were randomly divided into the free-BA and BA-LP groups (100 mg/kg BA; n = 5 mice at each time point). The two groups were intravenously administered with drugs via the tail vein, separately. Blood samples were collected from the submandibular vein with heparinized microblood collecting tubes at 5, 15, 30, 60, 90, 120, 240, 360, and 480 min after administration and centrifuged at 3500 rpm for 10 min. Plasma was collected and stored at -20°C until further analysis. After euthanasia, their livers, hearts, spleens, lungs, and kidneys were quickly harvested, the blood in the surface was washed with normal saline, and then, they were dried with filter paper, which were collected for BA concentration measurement.

After weighing, the tissues were homogenized with normal saline as the ratio 1:2 (weight: volume), except the spleens as 1:4 (weight: volume). All the plasma and tissues homogenate samples were treated as follows: 300 μL samples were placed into centrifuge tubes and vortexed for 1 min with 60 μL hydrochloric acid (1 mol/L). After adding 40 μL internal standard (RU) and 1.2 mL acetonitrile, the mixture was vortexed for 3 min and then centrifuged at 12000 rpm for 10 min. The obtained supernatant was evaporated under nitrogen atmosphere in a water bath at 36°C. The residue was dissolved in 100 μL methanol (70%) and vortexed for 5 min and centrifuged at 15000 rpm for 10 min. Then, we get the supernatant, and 20 μL solution was injected into the HPLC system.
All the samples were measured on a high-performance liquid chromatography (HPLC) system (Thermo Fisher Scientific, USA) via an AQ-C18 (4.6 × 250 mm) analytical column. The HPLC conditions were methanol-water-phosphoric acid (41:59:0.2, v/v/v) at the flow rate of 1 mL/min, detection wavelength for 276 nm, and a column temperature of 35°C.

### 2.4.2. Validation of HPLC Analytical Method

#### (1) Preparation of Related Solutions

The BA standard was precisely weighed and dissolved with methanol to obtain a stock solution of 1516 μg/mL and diluted to 485.12, 194.048, 97.024, 19.4048, 9.7024, 4.8512, 2.4256, and 1.4554 μg/mL with methanol.

The RU reference was accurately weighed to prepare a stock solution with a concentration of 501.6 μg/mL with methanol. The solution was diluted with methanol to prepare the stock solution of 100.32 μg/mL, which was the internal standard working solution.

#### (2) Specificity and Linearity

Full validation of the method was performed in blank plasma and tissue homogenate of mouse. Taking them with the BA reference substance and RU reference substance to prepare samples, the specificity of the method was evaluated based on whether the plasma and tissue endogenous substances had influence on the BA and RU.

Taking the blank plasma (300 μL) or tissue homogenate (300 μL) with the BA working solution (80 μL) of different concentrations, please refer to Section 2.4.1 for the next steps. The prepared sample was injected into HPLC for recording the peak area of BA and RU, and then, the ratio of BA to RU peak area (y) was used to regress the mass concentration of BA (x) with the least-square method to obtain the standard curve.

### Table 1: Regression equations, correlation coefficients, and linear ranges of BA in mouse plasma and tissues.

| Analyte  | Regression equation | Correlation coefficients | Linear ranges (μg/mL) |
|----------|---------------------|--------------------------|-----------------------|
| Plasma   | $Y = 0.224X + 0.05$ | 1                        | 4.8512-1516           |
| Heart    | $Y = 0.208X + 0.048$| 1                        | 1.4554-97.024         |
| Liver    | $Y = 0.186X + 0.026$| 0.999                    | 2.4256-194.048        |
| Spleen   | $Y = 0.185X - 0.034$| 0.999                    | 4.8512-194.048        |
| Lung     | $Y = 0.174X + 0.027$| 0.999                    | 2.4255-97.024         |
| Kidney   | $Y = 0.164X - 0.135$| 0.999                    | 2.4256-1516           |

### Table 2: The results of intraday and interday precision and accuracy for BA in blank plasma and tissues (n = 5 for intra-day and n = 5*3 for interday).

| Analyte  | Concentration (μg/mL) | Intraday     | Interday     |
|----------|-----------------------|--------------|--------------|
|          |                       | Precision (%) | Accuracy (%) | Precision (%) | Accuracy (%) |
| Plasma   | 4.8512                | 5.80%        | 100.01%      | 5.46%         | 99.86%       |
|          | 97.024                | 2.67%        | 99.37%       | 3.08%         | 99.00%       |
|          | 1516                  | 1.30%        | 99.06%       | 1.29%         | 98.46%       |
| Heart    | 1.4554                | 4.26%        | 98.38%       | 5.01%         | 98.19%       |
|          | 19.4048               | 2.44%        | 101.65%      | 3.40%         | 101.29%      |
|          | 97.024                | 1.38%        | 99.90%       | 1.41%         | 100.02%      |
| Liver    | 2.4256                | 3.15%        | 99.92%       | 4.58%         | 100.70%      |
|          | 48.512                | 4.16%        | 98.25%       | 3.50%         | 98.46%       |
|          | 194.048               | 1.29%        | 100.60%      | 1.20%         | 100.58%      |
| Spleen   | 4.8512                | 2.99%        | 99.77%       | 6.13%         | 99.04%       |
|          | 48.512                | 2.26%        | 99.64%       | 3.47%         | 99.85%       |
|          | 194.048               | 1.04%        | 100.12%      | 1.10%         | 100.30%      |
| Lung     | 2.4256                | 2.07%        | 100.97%      | 3.34%         | 100.04%      |
|          | 19.40475              | 8.58%        | 95.32%       | 6.45%         | 98.97%       |
|          | 97.024                | 2.45%        | 100.94%      | 7.51%         | 101.20%      |
| Kidney   | 2.4256                | 4.73%        | 97.93%       | 4.58%         | 99.20%       |
|          | 97.024                | 1.50%        | 99.73%       | 1.51%         | 99.86%       |
|          | 1516                  | 1.02%        | 98.67%       | 1.18%         | 98.63%       |
(3) Precision and Accuracy. Three BA concentrations were selected as the high, medium, and low concentrations. After preparation, the sample was injected 5 times within one day to obtain intraday precision. The interday precision was obtained for 3 days. The precision was evaluated as the relative standard deviation (RSD), and accuracy was expressed as the relative error (RE).

2.5. Modeling and Grouping. All mice were randomly divided into the following six groups: the control group, LPS group, LPS+BA (100 mg/kg) group, and LPS+BA-LP (50, 100, and 200 mg/kg) group. Different drug intervention groups were given intravenous injection of drugs daily for 3 days. One hour after the last administration, all animals, except the control group, received intratracheal drip of LPS (8 mg/kg) to induce the ALI models. The control group was intranasally received same normal saline. After 12 h of LPS stimulation, the mice were euthanized via cervical dislocation with chloral hydrate solution anesthetized. The bronchoalveolar lavage fluid (BALF) and lung tissues were obtained and stored for further experiments.

2.6. Lung Wet/Dry (W/D) Weight Ratio. The fresh lungs were collected and weighed to obtain wet weight. Then, the lungs were dehydrated at 80°C for 48 h [16] until weight remained unchanged to get the dry weight. Then, the W/D ratio of lung was calculated.

2.7. Histopathologic Evaluation of Lung Tissues. The lung tissues were obtained and fixed with 10% neutral formaldehyde. Lung tissues were treated by dehydration, pruning, embedding, sectioning, hematoxylin and eosin staining, sealing, and finally microscopic examination [17]. The severity of microscopic injury was graded from 0 (normal) to 5 (severe) in the following categories: interstitial edema, hemorrhage, hyaline membrane formation, necrosis, and congestion.

2.8. Determination of Protein and Inflammatory Factors in the BALF. After being sacrificed, the muscles in the neck of mice were separated to expose the trachea. And a catheter was inserted into the trachea via tracheostomy. The lung was lavaged with PBS, and then, the lavage liquid was collected and weighed to obtain wet weight. Then, the lungs were dehydrated at 80°C for 48 h [16] until weight remained unchanged to get the dry weight. After the mice were euthanized, the membranes in 5% nonfat milk dissolved in TBST for 1 h at 25°C, and then, membranes were incubated with an antibody. After dropping the fresh ECL solution to the membrane with protein side, the protein bands were detected by AlphaEaseFC software.

2.9. Western Blot Analysis. After the mice were euthanized, the whole lungs were collected, We grind the obtained tissue and extract the protein. The protein contents in the supernatant of the cracked lung were detected by BCA protein analysis kit. Then, samples were isolated from 10% SDS-polyacrylamide gel and transferred to the polyvinylidene difluoride (PVDF) membrane for protein detection. Blocking the membranes in 5% nonfat milk dissolved in TBST for 1 h at 25°C, and then, membranes were incubated with an antibody. After dropping the fresh ECL solution to the membrane with protein side, the protein bands were detected by AlphaEaseFC software.

Table 3: Main pharmacokinetic parameters of plasma in normal mice after intravenous injection of BA-LP and BA.

| Parameters | Units | BA-LP | BA |
|------------|-------|-------|----|
| AUC<sub>0-τ</sub> | mg/L·min | 17536.084 ± 928.392 | 2712.911 ± 55.945 |
| AUC<sub>0-∞</sub> | mg/L·min | 19574.508 ± 840.058 | 2958.151 ± 49.156 |
| MRT<sub>0-τ</sub> | min | 102.636 ± 1.749 | 17.354 ± 0.16 |
| MRT<sub>0-∞</sub> | min | 172.950 ± 14.110 | 41.167 ± 3.073 |
| t<sub>1/2</sub> | min | 202.963 ± 18.291 | 127.18 ± 10.849 |
| V<sub>d</sub> | L/kg | 1.500 ± 0.168 | 6.209 ± 0.582 |
| CLz | L/min/kg | 0.005 | 0.0338 ± 0.0004 |
| C<sub>max</sub> | mg/L | 192.689 ± 9.210 | 102.165 ± 1.788 |

BA-LP and BA were administered by intravenous injection at 100 mg/kg, and data were expressed as mean ± SD (n = 5).

![Figure 1: The plasma concentration-time profile of BA after i.v. administration of BA and BA-LP (100 mg/kg) in normal mice (n = 5).](image)

2.10. Statistical Analyses. All values are expressed as the means ± SEM. DAS3.0 (Mathematical Pharmacology Professional Committee of China, Shanghai, China) was used to calculate the in vivo pharmacokinetic parameters by a non-compartmental model. The statistical package was performed on SPSS 22.0 (SPSS Inc., Chicago, IL, USA) software. Differences between groups were analyzed using a one-way ANOVA (Dunnett’s t-test) and two-tailed Student’s t-test. The results were considered statistically significant at P < 0.05.

3. Results

3.1. Pharmacokinetics Study

3.1.1. Method Validation. As shown in Table 1, the calibration curve of BA in the mouse plasma and tissue homogenate was determined in a certain range, and the correlation coefficient was greater than 0.990, showing the good linearity.
Table 4: The concentrations of BA in tissues of normal mice after intravenous injection of BA-LP and BA.

| Time (min) | Heart (μg/g) | Liver (μg/g) | Spleen (μg/g) | Lung (μg/g) | Kidney (μg/g) |
|------------|--------------|--------------|---------------|-------------|--------------|
|            | BA-LP        | BA           | BA-LP         | BA          | BA-LP        | BA            | BA-LP        | BA            |
| 5          | 4.41 ± 0.59 | 2.97 ± 0.46 | 21.42 ± 1.19 | 17.02 ± 1.14 | 15.21 ± 1.09 | 3.68 ± 0.60   | 8.29 ± 1.33  | 5.49 ± 0.86   | 92.21 ± 9.86  | 226.61 ± 12.11|
| 15         | 5.35 ± 1.04 | 3.87 ± 0.45 | 31.47 ± 1.48 | 18.57 ± 1.63 | 22.71 ± 2.02 | 9.02 ± 0.73   | 15.51 ± 2.13  | 7.59 ± 0.80   | 77.25 ± 6.52  | 53.97 ± 3.30  |
| 30         | 7.52 ± 0.73 | 2.49 ± 0.32 | 61.79 ± 1.41 | 5.04 ± 0.86  | 25.50 ± 1.38 | 7.49 ± 0.54   | 10.58 ± 1.67  | 3.87 ± 0.65   | 35.56 ± 3.48  | 14.07 ± 1.49  |
| 60         | 7.51 ± 0.59 | 0.44 ± 0.06 | 50.34 ± 1.81 | 1.93 ± 0.07  | 49.71 ± 2.11 | 5.01 ± 0.25   | 15.30 ± 0.92  | 2.09 ± 0.54   | 17.94 ± 2.19  | 4.63 ± 0.28   |
| 90         | 5.44 ± 0.55 | 0.38 ± 0.04 | 18.44 ± 1.18 | 1.00 ± 0.04  | 16.51 ± 1.56 | 4.72 ± 0.19   | 8.41 ± 1.11   | 1.32 ± 0.04   | 9.76 ± 0.74   | 3.56 ± 0.20   |
| 120        | 1.73 ± 0.24 | ND           | 2.24 ± 0.18  | 0.45 ± 0.03  | 8.08 ± 0.69  | ND            | 3.69 ± 0.82   | 0.70 ± 0.03   | 5.48 ± 0.35   | 2.41 ± 0.18   |
| 240        | 1.27 ± 0.09 | ND           | 4.26 ± 0.46  | ND           | 6.55 ± 0.42  | ND            | 3.59 ± 0.42   | ND            | 4.43 ± 0.28   | ND           |
| 360        | 1.07 ± 0.14 | ND           | 3.12 ± 0.52  | ND           | 5.89 ± 0.57  | ND            | 1.77 ± 0.12   | ND            | 3.76 ± 0.30   | ND           |
| 480        | 0.87 ± 0.08 | ND           | 1.35 ± 0.05  | ND           | 5.25 ± 0.65  | ND            | 1.55 ± 0.09   | ND            | 3.04 ± 0.15   | ND           |

BA-LP and BA were administered by intravenous injection at 100 mg/kg, and data were expressed as mean ± SD (n = 5).
As Table 2 shows, both RSD% in the intraday and interday precisions of these concentrations of the plasma and tissues were less than 15%, indicating that the method had a good precision. And the intraday accuracy range was 95.32-101.65%, while the interday accuracy range of BA in three concentrations were 98.19-101.29%, which are in accordance with the guide.

3.1.2. Pharmacokinetics of Baicalin in Plasma of Mice. The plasma concentration of BA and BA-LP was investigated by using normal mice. Figure 1 showed that the plasma BA concentration versus time profiles in mouse plasma following i.v. administration of BA-LP and BA in normal mice at a dose of 100 mg/kg. As shown in Table 3, the AUC0-12 h of BA-LP was about 6.46 times of BA (17536.084 ± 928.392 mg/L*min vs. 2712.911 ± 55.945 mg/L*min), which was significantly higher than that of BA (P < 0.05), indicating that BA-LP had a better absorption than BA in mice. The MRT 0-12 h of BA-LP was higher than BA (P < 0.001), and the t1/2 values of the BA-LP and BA groups were 202.963 ± 18.291 min and 127.18 ± 10.849 min, respectively, which meant that the retention time of BA-LP was longer than that of BA. The Vd can reflect the distribution of BA in the tissue, and Vd value of BA-LP was about 1/4 of BA (1.500 ± 0.168 L/kg vs. 6.209 ± 0.582 L/kg, P < 0.05), indicating that BA-LP was easier to enter the blood circulation than tissue.

3.1.3. Tissue Distributions. As shown in Table 4, the distributions of BA were detected in the heart, liver, spleen, lung, and kidney of normal mice after intravenous injection of BA-LP and BA at 100 mg/kg. These results indicated that the distributions of BA in the heart, liver, spleen, and lung increased appreciably, while the content of BA in the kidney reduced relatively after the injection of BA-LP compared with BA. The BA targeting parameters of Te, TI, Ce, and RTE in different tissues after intravenous administration with BA-LP and BA in normal mice were shown in Table 5. We can find that BA-LP had certain targeting to the liver, heart, spleen, and lung, and the highest is to the liver, from these targeting parameters. Te indicated the selective targeting of the drug delivery system to a tissue; the larger the Te, the more targeted the drug delivery system is to the tissue. If TI > 1, it meant that the drug had targeting effects on some tissues; the higher the TI value, the greater the targeting. RTE can reflect the tendency distributions of different preparations of the same drug to tissues. The positive value of RTE indicates that it has a strong targeting effect on the tissue; otherwise, it has no targeting effect.

3.2. The Effect of Baicalin on Lung W/D Ratio. In this study, the pulmonary edema was evaluated by measuring the lung W/D ratio (Figure 2). The results showed that the lung W/D ratio was significantly higher than the control group after LPS administration (P < 0.05). However, after intervention of the BA, the W/D ratio was significantly reduced (P < 0.05), which showed that the BA could protect the lung injury. While at the same dose (100 mg/kg), BA-LP was more effective than BA in reducing the W/D ratio (P < 0.001). Furthermore, the high dosage of BA showed a much better therapeutic effect than the low dosage group (P < 0.01), indicating that the protective effect was dose dependent.

3.3. The Effect of Baicalin on Histopathology Changes of Lung Tissues. To evaluate the pathological changes of the lung tissues, hematoxylin and eosin (H&E) staining and a lung injury score system were carried out in this study. As shown in Figure 3, the lung tissues of the LPS group showed some obvious inflammation alterations, such as inflammatory cell infiltration, alveolar wall thickening, pulmonary congestion, and fibrous hyperplasia, while there were no obvious pathological changes in the control group. After treatment, BA markedly alleviated the lung injury score induced by LPS (P < 0.05) in a dose-dependent manner. In addition, BA-LP showed a better effect than BA in reducing the pathological changes at the same dose (100 mg/kg). The scores were shown in Figure 3(g), the mean pathological score was significantly increased after LPS-induced ALI compared with the control group (P < 0.05), while BA intervention groups could reduce the pathological score.

3.4. The Effect of BA on Protein Concentrations in BALF. To determine the levels of proteins and cytokines in BALF, BALF was collected 12 h after LPS challenge. As shown in Figure 4,
the total protein concentrations in BALF were significantly increased after LPS administration \( (P < 0.01) \). BA efficiently reduced the protein concentration in varied doses \((50, 100,\) and \(200 \text{ mg/kg})\), and BA-LP had a better therapeutic effect than BA at the same dosage of BA \((100 \text{ mg/kg}, P < 0.05)\).

### 3.5. The Effects of BA on TNF-α and IL-1β in BALF

The effect of BA on TNF-α and IL-1β production in BALF were analyzed at 12 h after LPS challenge by ELISA kits. As shown in Figure 5, the concentrations of TNF-α and IL-1β in BALF were significantly increased after LPS injection \((P < 0.01)\), while BA can significantly reduce the content of inflammatory factors TNF-α \((P < 0.05)\) and IL-6 \((P < 0.05)\). In addition, the inhibitory effects of BA-LP on TNF-α and IL-1β were much better than that of BA at 100 mg/kg \((P < 0.01, P < 0.05)\). In addition, the LPS+BA \((100 \text{ mg/kg})\) group had no significant difference with the LPS+BA-LP \((50 \text{ mg/kg})\) group.
3.6. The Effect of BA on TLR4/JNK/ERK/NF-κB Signaling Pathway. TLR can induce inflammatory responses after being activated by LPS, and NF-κB is located at the key position of the TLR downstream signaling pathway. The TLR4-NF-κB signaling pathway plays an important role in the regulation of LPS-induced ALI [18–21]. MAPK signaling pathways are also important ways of TLR4 initiation [22], which are regulated by a characteristic phosphorelay system in which a series of protein kinases phosphorylate, such as JNK and ERK [23]. We detected some key proteins using western blot experiments to explore the mechanisms of BA treatment on ALI. After 12 h of LPS injection, the expression of TLR4 and the phosphorylation of NF-κBp65, JNK, and ERK were markedly increased (Figure 6, $P < 0.01$, $P < 0.01$, and $P < 0.01$ vs. the control group; $P < 0.05$ and $P < 0.01$ vs. the LPS group; and $P < 0.05$ and $P < 0.01$ vs. the LPS + BA group). Additionally, there was no difference in the expression of total NF-κBp65, JNK, and ERK among these groups. As shown in Figure 6, treatment with BA could inhibit the phosphorylation of NF-κBp65, JNK, and ERK. While there was no significant difference between the LPS + BA (100 mg/kg) and LPS + BA-LP (50 mg/kg) groups in the TLR4/β-actin ratio, the same as the LPS + BA (100 mg/kg) and LPS + BA-LP (100 mg/kg) groups in the p-JNK/β-actin ratio, which indicated that BA may regulate inflammatory response via suppressing the TLR4/JNK/ERK/NF-κB signaling pathway.

4. Discussion

BA is widely used in the treatment of infection, pneumonia, hepatitis, and other diseases. But it has a low solubility and is easy to be eliminated in vivo. When BA-LP was injected into mice via the vein, the predominant targeting organ is the liver, and the drug distribution in the kidney is less, which greatly decreases the nephrotoxicity. It is reported that BA has a certain intervention effect on ALI due to its notable anti-inflammatory effects. However, BA has a low bioavailability and short half-life in vivo, which are easy to eliminate. Passive targeting can be achieved by controlling the particle size of liposomes. Liposomes with a particle size greater than 5 μm are easy to be trapped by the capillaries of the lungs. Encapsulating drugs in large-particle liposomes can achieve their accumulation. Therefore, it is helpful that making BA into liposomes to increase the targeting of drugs in lung lesions. Pharmacokinetic parameters showed that BA-LP had a longer half-life and more retention dosage than BA. In addition, the concentration of BA-LP in the lung tissue increased compared with that of BA, which suggested that BA-LP may be more efficient than BA in the treatment of lung diseases.

LPS is located on the surface of Gram-negative bacilli. The compound formed by LPS and its receptor can activate the CD14 [24] receptor on monocyte, macrophage, and other cells and lead to the production of inflammatory mediators. Therefore, LPS was commonly used to establish the animal models of ALI. Inflammation plays an important role in the course of ALI [25, 26], so we treat the ALI from the perspective of an anti-inflammatory effect.

The basic pathophysiological change of ALI/ARDS is noncardiogenic pulmonary edema caused by the increase of pulmonary capillary endothelial permeability and alveolar epithelium [27]. The edema fluid is rich in protein, and many kinds of inflammatory cells mainly composed of neutrophils. Inflammatory cells, alveolar epithelial cells and fibroblasts can produce a variety of cytokines, which can aggravate the inflammatory process and cause lung injury [4]. In this study, we observed that the W/D of the lung tissue of LPS-induced mice significantly increased, while the pulmonary edema of model animals was significantly improved under the intervention of BA. Total protein and inflammatory factors of the ALI mice in BALF were all increased, which indicated that the inflammation was produced after the established model, while the inflammation was significantly alleviated by the treatment of BA. The H&E-stained histopathological tissue section can show the degree of lung injury. After BA intervention, the degree of lung injury in ALI mice was significantly reduced. In the whole experiment, it was found that the therapeutic effect of BA-LP was better than that of BA at the same dose, and the effects exhibited an obvious dose-dependent manner.

As an initiator of excessive inflammation, TNF-α, which has a significant inflammatory effect, plays a major role in the inflammatory response. Similar to IL-1β, TNF-α can stimulate immune cells to produce more inflammatory factors and mediators through autocrine and paracrine mechanisms [28]. Previous investigations have demonstrated that the NF-κB pathway plays the essential role in the inflammation-related diseases, and inhibition of the NF-κB signaling transduction would be beneficial for the control and treatment of these inflammatory disorders [29, 30]. In the present study, the expression of NF-κBp65 and the content of TNF-α and IL-1β increased after LPS administration, suggesting that the expression of NF-κBp65 is easy to be eliminated in vivo.

![Figure 4: BA alleviates the total proteins in BALF induced by LPS. After 12 h of LPS administration, mice were sacrificed to get the BALF. The values were presented as means ± SD ($n = 4$). $P < 0.05$, **$P < 0.01$, and ***$P < 0.001$ vs. the control group; $P < 0.05$ and **$P < 0.01$ vs. the LPS group; and $P < 0.05$ and ***$P < 0.001$ vs. the LPS + BA group.](image-url)
κBp65 promoted the release of inflammatory mediators. BA-LP had an inhibitory effect on inflammatory factors in BALF, indicating that BA treats acute lung injury through anti-inflammatory effects.

Activation of the JNK-ERK signaling pathway is one of the early intracellular events after LPS acts on monocyte/macrophage, which is closely related to the synthesis and secretion of inflammatory cytokines [31]. It has been found that JNK-ERK signaling is involved in LPS-stimulated gene transcription and protein expression of inflammatory and anti-inflammatory cytokines. The JNK-ERK signaling pathway is necessary for the transcription and translation of TNF-α [32], and the activation of JNK is one of the conditions for TNF-α mRNA translation. ERK is the most important link of monocyte inflammatory response to LPS. The network inflammatory cascade produced by LPS is complex. The signal pathways endow the uniqueness of the biological reaction, which provides an alternative target for the treatment of LPS-induced inflammatory response. The present experiment showed that BA could reduce the key protein of the
TLR4/JNK/ERK/NF-κB signal pathway and block the transmission of the pathological signal.

In this paper, we found that the BA-LP had longer retention time and more concentration in lungs than BA in normal mice. In addition, pharmacological experiments showed that BA-LP had a better therapeutic effect on ALI than BA. BA can treat LPS-induced ALI through anti-inflammatory by regulating the TLR4/JNK/ERK/NF-κB signaling pathway. These findings suggest that BA-LP may be a new way for preventing and treating ALI. However, the occurrences and treatments of these diseases are complex. In the process of treatment of BA for ALI, other deep mechanisms may also be involved which needs further research.

Data Availability

The data used to support the findings of this study are included within the article.

Additional Points

Highlights. The retention time of baicalin liposome is longer than that of the baicalin monomer, and the concentration in the lung is higher in vivo. Baicalin liposome can protect against lipopolysaccharide-induced acute lung injury in mice by an anti-inflammatory effect at a dosage-dependent manner. The expression of key proteins in the TLR4/NF-κB and JNK/ERK signaling pathways were upregulated after the treatment of baicalin.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Yu Long and Yan Xiang contribute the same to this article; both of them are first authors.

Acknowledgments

This work was funded by the National Natural Science Foundation of China (grant number 81673615), the Sichuan Provincial Administration of Traditional Chinese Medicine Research Project (grant numbers 2018QN009), the Xinglin Scholar Discipline Promotion Talent Program of Chengdu University of Traditional Chinese Medicine (grant numbers QNXZ2018018, XGZX2010), the Sichuan Human Resources and Social Security Bureau (grant number 00809503), the National training program for talents of traditional Chinese medicine characteristic technology inheritance (grant number T20194828003) and the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine (grant number TCM-201908).

Supplementary Materials

Graphical abstract: Tissues distributions of BA-LP in normal mice and the intervention of BA-LP on LPS-induced ACL in mice. (Supplementary Materials)

References

[1] S. Gando, T. Kameue, N. Matsuda, A. Sawamura, M. Hayakawa, and H. Kato, “Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation,” Inflammation, vol. 28, no. 4, pp. 237–244, 2004.
[2] E. Fan, D. Brodie, and A. S. Slutsky, “Acute respiratory distress syndrome,” Journal of the American Medical Association, vol. 319, no. 7, pp. 698–710, 2018.
[3] Y. N. Yang, Z. Ding, Y. Wang et al., “Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury,” Journal of Cellular and Molecular Medicine, vol. 24, no. 9, pp. 5039–5056, 2020.
[4] X. Y. Hu, Y. Tian, S. H. Qu et al., “Protective effect of TM6 on LPS-induced acute lung injury in mice,” Scientific Reports, vol. 7, no. 1, article 572, 2017.
[5] J. Reutershans, A. Basit, E. V. Galkina, and K. Ley, “Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 289, no. 5, pp. L807–L815, 2005.
[6] S. Nonas, I. Miller, K. Kawkitinarong et al., “Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 10, pp. 1130–1138, 2006.
[7] B. Wang, X. Gong, J. Y. Wan et al., “Resolvin D1 protects mice from LPS-induced acute lung injury,” Pulmonary Pharmacology & Therapeutics, vol. 24, no. 4, pp. 434–441, 2011.
[8] Y. L. Wu, F. Wang, L. H. Fan et al., “Baicalin alleviates atherosclerosis by relieving oxidative stress and inflammatory responses via inactivating the NF-κB and p38 MAPK signaling pathways,” Biomedicine & Pharmacotherapy, vol. 97, pp. 1673–1679, 2018.
[9] Y. Long, Q. Yang, Y. Xiang et al., “Nose to brain drug delivery - A promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion," Pharmacological Research, vol. 159, p. 104795, 2020.
[10] H. G. Chen, Y. F. Xu, J. Z. Wang, W. Zhao, and H. H. Ruan, “Baicalin ameliorates isoproterenol-induced acute myocardial infarction through iNOS, inflammation and oxidative stress in rat,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp. 10139–10147, 2015.
[11] K. Sowndhararajan, P. Deepa, M. Kim, S. Park, and S. Kim, “Neuroprotective and cognitive enhancement potentials of baicalin: a review,” Brain Sciences, vol. 8, no. 6, p. 104, 2018.
[12] X. Gao, M. Guo, Z. Zhang, P. Shen, Z. Yang, and N. Zhang, “Baicalin promotes the bacteriostatic activity of lysozyme on S. aureus in mammary glands and neutrophilic granulocytes in mice,” Oncotarget, vol. 8, no. 12, pp. 19894–19901, 2017.
[13] X. Meng, L. Hu, and W. Li, “Baicalin ameliorates lipopolysaccharide-induced acute lung injury in mice by suppressing oxidative stress and inflammation via the activation of the Nrf2-mediated HO-1 signaling pathway,” Naunyn-
Schmiedeberg’s Archives of Pharmacology, vol. 392, no. 11, pp. 1421–1433, 2019.

14. T. Huang, Y. Liu, and C. Zhang, “Pharmacokinetics and bioavailability enhancement of baicalin: a review,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 44, no. 2, pp. 159–168, 2019.

15. N. Li, L. Feng, Y. Tan, Y. Xiang, R. Zhang, and M. Yang, “Preparation, characterization, pharmacokinetics and biodistribution of baicalin-loaded liposome on cerebral ischemia-reperfusion after i.v. administration in rats,” Molecules, vol. 23, no. 7, p. 1747, 2018.

16. S. Fu, W. Lu, W. Yu, and J. Hu, “Protective effect of Cordyceps sinensis extract on lipopolysaccharide-induced acute lung injury in mice,” Bioscience Reports, vol. 39, no. 6, 2019.

17. J. Lei, Y. Wei, P. Song et al., “Cordycepin inhibits LPS-induced acute lung injury by inhibiting inflammation and oxidative stress,” European Journal of Pharmacology, vol. 818, pp. 110–114, 2018.

18. P. Moine, R. McIntyre, M. D. Schwartz et al., “NF-κB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome,” Shock, vol. 13, no. 2, pp. 85–91, 2000.

19. L. J. Tao, F. Y. Cao, G. H. Xu, H. F. Xie, M. Zhang, and C. F. Zhang, “Mogroside IIIE attenuates LPS-induced acute lung injury in mice partly through regulation of the TLR4/MAPK/NF-κB axis via AMPK activation,” Phytotherapy Research, vol. 31, no. 7, pp. 1097–1106, 2017.

20. Z. Tianzhu and W. Shumin, “Esculin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of TLR/NF-κB pathways,” Inflammation, vol. 38, no. 4, pp. 1529–1536, 2015.

21. C. Xu, G. Chen, W. Yang et al., “Hyaluronan ameliorates LPS-induced acute lung injury in mice via toll-like receptor (TLR) 4-dependent signaling pathways,” International Immunopharmacology, vol. 28, no. 2, pp. 1050–1058, 2015.

22. W. Wang, J. Weng, L. Yu, Q. Huang, Y. Jiang, and X. Guo, “Role of TLR4-p38 MAPK-Hsp27 signal pathway in LPS-induced pulmonary epithelial hyperpermeability,” BMC Pulmonary Medicine, vol. 18, no. 1, p. 178, 2018.

23. G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002.

24. S. Wright, R. Ramos, P. Tobias, R. Ulevitch, and J. Mathison, “CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein,” Science, vol. 249, no. 4975, pp. 1431–1433, 1990.

25. R. B. Goodman, J. Pugin, J. S. Lee, and M. A. Matthay, “Cytokine-mediated inflammation in acute lung injury,” Cytokine & Growth Factor Reviews, vol. 14, no. 6, pp. 523–535, 2003.

26. K. E. Welty-Wolf, M. S. Carraway, T. L. Ortel, and C. A. Pandadosi, “Coagulation and inflammation in acute lung injury,” Thrombosis and Haemostasis, vol. 88, no. 1, pp. 17–25, 2002.

27. T. Wang, “Basic and clinical research progress in acute lung injury/acute respiratory distress syndrome,” Infection International, vol. 7, no. 2, pp. 38–43, 2018.

28. A. Hiyama, S. Hiraishi, D. Sakai, and J. Mochida, “CCAAT enhancer binding protein β regulates the expression of tumor necrosis factor-α in the nucleus pulposus cells,” Journal of Orthopaedic Research, vol. 34, no. 5, pp. 865–875, 2016.